Startups
Sudo Biosciences
Carmel, Indiana, United States · London, United Kingdom
Biotechnology company based in Carmel, Indiana and London, developing selective small molecule TYK2 inhibitors for neurological and immune-mediated diseases. Its oral brain-penetrant SUDO-550 program targets multiple sclerosis and neuroinflammatory conditions; the company reported Phase 1 results in October 2025 and planned a Phase 2 study, whose initiation remains unverified. Its published pipeline also lists the topical dermatology candidate SUDO-286 in Phase 1 and an ophthalmic program in preclinical development. Founded in 2020 and backed by specialist life science investors.
Founded 2020
Team
 Anitha JeyanthanR&D Project Management |
 Anjali PandeySenior Vice President, Medicinal Chemistry |
Chris GagliardiDirector |
 Cliona MacSweeneyHead of Translational Medicine |
Dan EstesDirector · Co-Founder |
Dave JohnsonDirector |
 David HenningsSenior Vice President, Chemistry, Manufacturing and Controls |
 Edd FlemingDirector |
 Fenella SmithExecutive Assistant |
 Gerry ThomasHead of R&D Project Management |
 Gordon McMurrayChief Development Officer |
 Ian MillsChief Medical Officer |
 Imran BabarChief Business & Financial Officer |
 Jack KempsterAccountant |
 Kejal PatelVice President, Clinical Operations |
 Kelly MunroClinical Pharmacology |
 Mark EvansNeuropharmacology |
 Marsilio AdrianiDirector, Translational Biology |
 Matt NelanFinance |
 Paul BavierChief Legal Officer |
 Peadar O’DonohoeVice President, Clinical Development |
 Rachel EcclesVice President, Translational Pharmacology |
 Roy GrayVice President, Non-Clinical Development |
 Sally FillinghamClinical Trial Administration |
 Sarah Loughrey-JenningsClinical Trial Management |
 Scott ByrdChief Executive Officer · Director |
Shinichiro FuseDirector |
 Terrie Walker-SmithClinical Trial Management |
 Vassilios AslanisVice President, Clinical Pharmacology |
 Waylon ParhamVice President, Finance & Controller |
 Zainib ShabirClinical Trial Management |